Mucins in gastrointestinal cancers.

Michael S. Turner, John R. McKolanis, Ramesh K. Ramanathan, David C. Whitcomb, Olivera J. Finn

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

The mucin family has been under study by molecular biologists, biochemists, pathologists and immunologists interested in cancer because of the role these molecules can play in the diagnosis and treatment of cancer. Immense knowledge has been accumulated, but the high speed of progress in the laboratory has not been matched by the progress towards applying this knowledge in the clinic. For example, specific knowledge of cancer-associated changes in the expression and glycosylation of various mucins, which can aid in the diagnosis as well as prognosis of GI cancers, has not yet led to the use of a panel of anti-mucin antibodies as a standard diagnostic tool. Similarly, many more opportunities exist for using mucin-based therapies than are currently being considered in the clinic. This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future.

Original languageEnglish (US)
Pages (from-to)259-274
Number of pages16
JournalCancer chemotherapy and biological response modifiers
Volume21
StatePublished - 2003

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Turner, M. S., McKolanis, J. R., Ramanathan, R. K., Whitcomb, D. C., & Finn, O. J. (2003). Mucins in gastrointestinal cancers. Cancer chemotherapy and biological response modifiers, 21, 259-274.